Latest Updates
Investor Presentation Coming Soon
The B2i Digital team is pleased to introduce Applied DNA Sciences, Inc. (NASDAQ: BNBX) as a new B2i Digital Featured Company. A full company profile will be available soon at https://b2idigital.com/featured-companies.
Applied DNA Sciences is a Stony Brook, New York-based biotechnology company that has recently adopted a BNB-focused digital asset treasury strategy while continuing to commercialize its proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets. The company’s BNB strategy centers on managing digital assets, primarily BNB, the native cryptocurrency of the Binance ecosystem, to generate yield and token accumulation through staking, restaking, and other Binance-specific decentralized finance (DeFi) strategies.
In September 2025, the company raised approximately $27 million through a private placement involving both cash and cryptocurrency investors. The proceeds are being deployed to execute Applied DNA’s announced BNB treasury strategy, managed under a five-year Strategic Digital Assets Services Agreement with Cypress LLC, which provides discretionary asset management services. A related Strategic Advisor Agreement with Cypress Management LLC adds strategic and technical guidance. Together, these partnerships are designed to enhance yield generation, capital efficiency, and liquidity resilience within the Binance ecosystem.
To reflect this transformation, Applied DNA changed its Nasdaq ticker from “APDN” to “BNBX” effective October 7, 2025. The company describes this as a signal of its strategic commitment to integrating digital asset management alongside its ongoing biotechnology operations. Applied DNA is maintaining its LineaRx subsidiary, which continues to commercialize the company’s LineaDNA™, LineaRNAP™, and LineaIVT™ platforms. These cell-free DNA and RNA production technologies enable rapid and scalable manufacturing of synthetic DNA and mRNA for advanced therapeutics and diagnostics.
Applied DNA is led by Clay Shorrock, Chief Executive Officer and President; and Beth Jantzen, Chief Financial Officer. The company’s advisory team includes Anthony Scaramucci applied, Founder and Managing Partner of SkyBridge Capital, as Strategic Capital Markets Advisor; Patrick Horsman (CFA), as Chief Investment Officer (pending appointment); Josh Kruger, as Chairman of the Board (nominated); and JR Pasch, as Strategic Advisor.
To learn more about Applied DNA Sciences, Inc., visit https://investors.adnas.com. For investor inquiries, contact BnB@icrinc.com.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Applied DNA Sciences is a Stony Brook, New York-based biotechnology company that has recently adopted a BNB-focused digital asset treasury strategy while continuing to commercialize its proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets. The company’s BNB strategy centers on managing digital assets, primarily BNB, the native cryptocurrency of the Binance ecosystem, to generate yield and token accumulation through staking, restaking, and other Binance-specific decentralized finance (DeFi) strategies.
In September 2025, the company raised approximately $27 million through a private placement involving both cash and cryptocurrency investors. The proceeds are being deployed to execute Applied DNA’s announced BNB treasury strategy, managed under a five-year Strategic Digital Assets Services Agreement with Cypress LLC, which provides discretionary asset management services. A related Strategic Advisor Agreement with Cypress Management LLC adds strategic and technical guidance. Together, these partnerships are designed to enhance yield generation, capital efficiency, and liquidity resilience within the Binance ecosystem.
To reflect this transformation, Applied DNA changed its Nasdaq ticker from “APDN” to “BNBX” effective October 7, 2025. The company describes this as a signal of its strategic commitment to integrating digital asset management alongside its ongoing biotechnology operations. Applied DNA is maintaining its LineaRx subsidiary, which continues to commercialize the company’s LineaDNA™, LineaRNAP™, and LineaIVT™ platforms. These cell-free DNA and RNA production technologies enable rapid and scalable manufacturing of synthetic DNA and mRNA for advanced therapeutics and diagnostics.
Applied DNA is led by Clay Shorrock, Chief Executive Officer and President; and Beth Jantzen, Chief Financial Officer. The company’s advisory team includes Anthony Scaramucci applied, Founder and Managing Partner of SkyBridge Capital, as Strategic Capital Markets Advisor; Patrick Horsman (CFA), as Chief Investment Officer (pending appointment); Josh Kruger, as Chairman of the Board (nominated); and JR Pasch, as Strategic Advisor.
To learn more about Applied DNA Sciences, Inc., visit https://investors.adnas.com. For investor inquiries, contact BnB@icrinc.com.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Read more
B2i Digital
3 days ago
The B2i Digital team is pleased to introduce Applied DNA Sciences, Inc. (NASDAQ: BNBX) as a new B2i Digital Featured Company. A full company profile will be available soon at https://b2idigital.com/featured-companies.
Applied DNA Sciences is a Stony Brook, New York-based biotechnology company that has recently adopted a BNB-focused digital asset treasury strategy while continuing to commercialize its proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets. The company’s BNB strategy centers on managing digital assets, primarily BNB, the native cryptocurrency of the Binance ecosystem, to generate yield and token accumulation through staking, restaking, and other Binance-specific decentralized finance (DeFi) strategies.
In September 2025, the company raised approximately $27 million through a private placement involving both cash and cryptocurrency investors. The proceeds are being deployed to execute Applied DNA’s announced BNB treasury strategy, managed under a five-year Strategic Digital Assets Services Agreement with Cypress LLC, which provides discretionary asset management services. A related Strategic Advisor Agreement with Cypress Management LLC adds strategic and technical guidance. Together, these partnerships are designed to enhance yield generation, capital efficiency, and liquidity resilience within the Binance ecosystem.
To reflect this transformation, Applied DNA changed its Nasdaq ticker from “APDN” to “BNBX” effective October 7, 2025. The company describes this as a signal of its strategic commitment to integrating digital asset management alongside its ongoing biotechnology operations. Applied DNA is maintaining its LineaRx subsidiary, which continues to commercialize the company’s LineaDNA™, LineaRNAP™, and LineaIVT™ platforms. These cell-free DNA and RNA production technologies enable rapid and scalable manufacturing of synthetic DNA and mRNA for advanced therapeutics and diagnostics.
Applied DNA Sciences is a Stony Brook, New York-based biotechnology company that has recently adopted a BNB-focused digital asset treasury strategy while continuing to commercialize its proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets. The company’s BNB strategy centers on managing digital assets, primarily BNB, the native cryptocurrency of the Binance ecosystem, to generate yield and token accumulation through staking, restaking, and other Binance-specific decentralized finance (DeFi) strategies.
In September 2025, the company raised approximately $27 million through a private placement involving both cash and cryptocurrency investors. The proceeds are being deployed to execute Applied DNA’s announced BNB treasury strategy, managed under a five-year Strategic Digital Assets Services Agreement with Cypress LLC, which provides discretionary asset management services. A related Strategic Advisor Agreement with Cypress Management LLC adds strategic and technical guidance. Together, these partnerships are designed to enhance yield generation, capital efficiency, and liquidity resilience within the Binance ecosystem.
To reflect this transformation, Applied DNA changed its Nasdaq ticker from “APDN” to “BNBX” effective October 7, 2025. The company describes this as a signal of its strategic commitment to integrating digital asset management alongside its ongoing biotechnology operations. Applied DNA is maintaining its LineaRx subsidiary, which continues to commercialize the company’s LineaDNA™, LineaRNAP™, and LineaIVT™ platforms. These cell-free DNA and RNA production technologies enable rapid and scalable manufacturing of synthetic DNA and mRNA for advanced therapeutics and diagnostics.
Read more
@b2i_digital
3 days ago
The B2i Digital team is pleased to introduce Applied DNA Sciences, Inc. (NASDAQ: BNBX) as a new B2i Digital Featured Company. A full company profile will be available soon at https://b2idigital.com/featured-companies. Applied DNA Sciences is a Stony Brook, New York-based biotechnology company that has recently adopted a BNB-focused digital asset treasury strategy while continuing to commercialize its proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets. The company’s BNB strategy centers on managing digital assets, primarily BNB, the native cryptocurrency of the Binance ecosystem, to generate yield and token accumulation through staking, restaking, and other Binance-specific decentralized finance (DeFi) strategies. In September 2025, the company raised approximately $27 million through a private placement involving both cash and cryptocurrency investors. The proceeds are being deployed to execute Applied DNA’s announced BNB treasury strategy, managed under a five-year Strategic Digital Assets Services Agreement with Cypress LLC, which provides discretionary asset management services. A related Strategic Advisor Agreement with Cypress Management LLC adds strategic and technical guidance. Together, these partnerships are designed to enhance yield generation, capital efficiency, and liquidity resilience within the Binance ecosystem. To reflect this transformation, Applied DNA changed its Nasdaq ticker from “APDN” to “BNBX” effective October 7, 2025. The company describes this as a signal of its strategic commitment to integrating digital asset management alongside its ongoing biotechnology operations. Applied DNA is maintaining its LineaRx subsidiary, which continues to commercialize the company’s LineaDNA™, LineaRNAP™, and LineaIVT™ platforms. These cell-free DNA and RNA production technologies enable rapid and scalable manufacturing of synthetic DNA and mRNA for advanced therapeutics and diagnostics. Applied DNA is led by Clay Shorrock, Chief Executive Officer and President; and Beth Jantzen, Chief Financial Officer. The company’s advisory team includes Anthony Scaramucci applied, Founder and Managing Partner of SkyBridge Capital, as Strategic Capital Markets Advisor; Patrick Horsman (CFA), as Chief Investment Officer (pending appointment); Josh Kruger, as Chairman of the Board (nominated); and JR Pasch, as Strategic Advisor. To learn more about Applied DNA Sciences, Inc., visit https://investors.adnas.com. For investor inquiries, contact BnB@icrinc.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.#investing #stocks #finance
Read more
b2idigital
3 days ago
The B2i Digital team is pleased to introduce Applied DNA Sciences, Inc. (NASDAQ: BNBX) as a new B2i Digital Featured Company. A full company profile will be available soon at https://b2idigital.com/featured-companies.
Applied DNA Sciences is a Stony Brook, New York-based biotechnology company that has recently adopted a BNB-focused digital asset treasury strategy while continuing to commercialize its proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets. The company’s BNB strategy centers on managing digital assets, primarily BNB, the native cryptocurrency of the Binance ecosystem, to generate yield and token accumulation through staking, restaking, and other Binance-specific decentralized finance (DeFi) strategies.
In September 2025, the company raised approximately $27 million through a private placement involving both cash and cryptocurrency investors. The proceeds are being deployed to execute Applied DNA’s announced BNB treasury strategy, managed under a five-year Strategic Digital Assets Services Agreement with Cypress LLC, which provides discretionary asset management services. A related Strategic Advisor Agreement with Cypress Management LLC adds strategic and technical guidance. Together, these partnerships are designed to enhance yield generation, capital efficiency, and liquidity resilience within the Binance ecosystem.
To reflect this transformation, Applied DNA changed its Nasdaq ticker from “APDN” to “BNBX” effective October 7, 2025. The company describes this as a signal of its strategic commitment to integrating digital asset management alongside its ongoing biotechnology operations. Applied DNA is maintaining its LineaRx subsidiary, which continues to commercialize the company’s LineaDNA™, LineaRNAP™, and LineaIVT™ platforms. These cell-free DNA and RNA production technologies enable rapid and scalable manufacturing of synthetic DNA and mRNA for advanced therapeutics and diagnostics.
Applied DNA is led by Clay Shorrock, Chief Executive Officer and President; and Beth Jantzen, Chief Financial Officer. The company’s advisory team includes Anthony Scaramucci applied, Founder and Managing Partner of SkyBridge Capital, as Strategic Capital Markets Advisor; Patrick Horsman (CFA), as Chief Investment Officer (pending appointment); Josh Kruger, as Chairman of the Board (nominated); and JR Pasch, as Strategic Advisor.
To learn more about Applied DNA Sciences, Inc., visit https://investors.adnas.com. For investor inquiries, contact BnB@icrinc.com.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Applied DNA Sciences is a Stony Brook, New York-based biotechnology company that has recently adopted a BNB-focused digital asset treasury strategy while continuing to commercialize its proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets. The company’s BNB strategy centers on managing digital assets, primarily BNB, the native cryptocurrency of the Binance ecosystem, to generate yield and token accumulation through staking, restaking, and other Binance-specific decentralized finance (DeFi) strategies.
In September 2025, the company raised approximately $27 million through a private placement involving both cash and cryptocurrency investors. The proceeds are being deployed to execute Applied DNA’s announced BNB treasury strategy, managed under a five-year Strategic Digital Assets Services Agreement with Cypress LLC, which provides discretionary asset management services. A related Strategic Advisor Agreement with Cypress Management LLC adds strategic and technical guidance. Together, these partnerships are designed to enhance yield generation, capital efficiency, and liquidity resilience within the Binance ecosystem.
To reflect this transformation, Applied DNA changed its Nasdaq ticker from “APDN” to “BNBX” effective October 7, 2025. The company describes this as a signal of its strategic commitment to integrating digital asset management alongside its ongoing biotechnology operations. Applied DNA is maintaining its LineaRx subsidiary, which continues to commercialize the company’s LineaDNA™, LineaRNAP™, and LineaIVT™ platforms. These cell-free DNA and RNA production technologies enable rapid and scalable manufacturing of synthetic DNA and mRNA for advanced therapeutics and diagnostics.
Applied DNA is led by Clay Shorrock, Chief Executive Officer and President; and Beth Jantzen, Chief Financial Officer. The company’s advisory team includes Anthony Scaramucci applied, Founder and Managing Partner of SkyBridge Capital, as Strategic Capital Markets Advisor; Patrick Horsman (CFA), as Chief Investment Officer (pending appointment); Josh Kruger, as Chairman of the Board (nominated); and JR Pasch, as Strategic Advisor.
To learn more about Applied DNA Sciences, Inc., visit https://investors.adnas.com. For investor inquiries, contact BnB@icrinc.com.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Read more
B2i Digital, Inc.
3 days ago
The B2i Digital team is pleased to introduce Applied DNA Sciences, Inc. (NASDAQ: BNBX) as a new B2i Digital Featured Company. A full company profile will be available soon at https://b2idigital.com/featured-companies.
Applied DNA Sciences is a Stony Brook, New York-based biotechnology company that has recently adopted a BNB-focused digital asset treasury strategy while continuing to commercialize its proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets. The company’s BNB strategy centers on managing digital assets, primarily BNB, the native cryptocurrency of the Binance ecosystem, to generate yield and token accumulation through staking, restaking, and other Binance-specific decentralized finance (DeFi) strategies.
In September 2025, the company
Applied DNA Sciences is a Stony Brook, New York-based biotechnology company that has recently adopted a BNB-focused digital asset treasury strategy while continuing to commercialize its proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets. The company’s BNB strategy centers on managing digital assets, primarily BNB, the native cryptocurrency of the Binance ecosystem, to generate yield and token accumulation through staking, restaking, and other Binance-specific decentralized finance (DeFi) strategies.
In September 2025, the company
Read more
